Literature DB >> 7518351

Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.

B R Minev1, B J McFarland, P J Spiess, S A Rosenberg, N P Restifo.   

Abstract

CD8+ T-lymphocytes (TCD8+) recognize minimal peptides of 8-10 residues which are the products of intracellularly processed proteins and are presented at the cell surface by major histocompatibility complex class I molecules. An important step in this process is the translocation of processed proteins from the cytosol across the endoplasmic reticulum membrane, mediated by transporter associated with antigen-processing proteins or alternatively by endoplasmic reticulum-insertion signal sequences located at the NH2-terminus of the precursor molecules. We report here that the addition of an endoplasmic reticulum-insertion signal sequence at the NH2-terminus of TCD8+ epitopes from chicken ovalbumin (amino acids 257-264) or a naturally occurring tumor antigen expressed by the murine mastocytoma P815 (P1A amino acids 35-43) significantly enhanced the priming of specific TCD8+ in vivo. The signal sequence did not enhance peptide immunogenicity by merely increasing the hydrophobicity of the peptide, since ovalbumin amino acids 257-264 peptide with the signal sequence at its COOH-terminus did not demonstrate enhanced efficacy. The signal sequence did not act as a helper epitope, since TCD8+ responses were not diminished in class II-deficient transgenic mice or in mice depleted of CD4+ T-cells in vivo. Importantly, a single immunization with the fusion peptide significantly prolonged survival of mice challenged with E.G7OVA, a thymoma transfected with the complementary DNA of chicken ovalbumin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518351      PMCID: PMC2254935     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

Review 1.  Transport of proteins across the endoplasmic reticulum membrane.

Authors:  T A Rapoport
Journal:  Science       Date:  1992-11-06       Impact factor: 47.728

Review 2.  Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Adv Immunol       Date:  1992       Impact factor: 3.543

3.  Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer.

Authors:  T Spies; V Cerundolo; M Colonna; P Cresswell; A Townsend; R DeMars
Journal:  Nature       Date:  1992-02-13       Impact factor: 49.962

4.  Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct.

Authors:  J J Lasarte; P Sarobe; A Gullón; J Prieto; F Borrás-Cuesta
Journal:  Cell Immunol       Date:  1992-04-15       Impact factor: 4.868

5.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.

Authors:  D F Hunt; R A Henderson; J Shabanowitz; K Sakaguchi; H Michel; N Sevilir; A L Cox; E Appella; V H Engelhard
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

6.  In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help.

Authors:  C Fayolle; E Deriaud; C Leclerc
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

7.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

8.  Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide.

Authors:  B Lethé; B van den Eynde; A van Pel; G Corradin; T Boon
Journal:  Eur J Immunol       Date:  1992-09       Impact factor: 5.532

9.  Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.

Authors:  F Zhou; B T Rouse; L Huang
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

10.  CD8+ T cells specific for a single nonamer epitope of Listeria monocytogenes are protective in vivo.

Authors:  J T Harty; M J Bevan
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  27 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  Induction of cell-mediated immunity against Mycobacterium tuberculosis using DNA vaccines encoding cytotoxic and helper T-cell epitopes of the 38-kilodalton protein.

Authors:  D P Fonseca; B Benaissa-Trouw; M van Engelen; C A Kraaijeveld; H Snippe; A F Verheul
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 3.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

Review 4.  T-cell recognition of self peptides as tumor rejection antigens.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 5.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

6.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.

Authors:  S A Rosenberg; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; M E Dudley; S L Schwarz; P J Spiess; J R Wunderlich; M R Parkhurst; Y Kawakami; C A Seipp; J H Einhorn; D E White
Journal:  Nat Med       Date:  1998-03       Impact factor: 53.440

7.  New dimensions in vaccinology: A new insight.

Authors:  D Tomar; V Chattree; V Tripathi; A A Khan; A R Bakshi; D N Rao
Journal:  Indian J Clin Biochem       Date:  2005-01

8.  Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.

Authors:  D R Surman; M E Dudley; W W Overwijk; N P Restifo
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

Review 9.  The use of signal peptide domains as vaccine candidates.

Authors:  Riva Kovjazin; Lior Carmon
Journal:  Hum Vaccin Immunother       Date:  2014-10-30       Impact factor: 3.452

10.  Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Authors:  Adam Vigil; Osvaldo Martinez; Mark A Chua; Adolfo García-Sastre
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.